I think Liquidia has strong potential, especially considering the possibility of full FDA approval in 2025. With a price target of $30/share floating around, it seems like a promising swing trade opportunity as the market anticipates positive developments.

I believe LQDA is a solid long play despite their recent FDA setback, as they’re suing for their superior inhalation powder. With secured funding, I feel confident in holding my position at $8.62 while they fight this legal battle. There’s a lot of potential here.

Given the FDA's tentative approval of YUTREPIA and favorable analyst ratings, I believe Liquidia (LQDA) has significant growth potential, promising substantial returns. Additionally, the removal of legal injunctions boosts prospects for final FDA approval soon, enhancing LQDA’s market position.